Literature DB >> 28554406

Clinical Assessments in Parkinson's Disease: Scales and Monitoring.

Roongroj Bhidayasiri1, Pablo Martinez-Martin2.   

Abstract

Measurement of disease state is essential in both clinical practice and research in order to assess the severity and progression of a patient's disease status, effect of treatment, and alterations in other relevant factors. Parkinson's disease (PD) is a complex disorder expressed through many motor and nonmotor manifestations, which cause disabilities that can vary both gradually over time or come on suddenly. In addition, there is a wide interpatient variability making the appraisal of the many facets of this disease difficult. Two kinds of measure are used for the evaluation of PD. The first is subjective, inferential, based on rater-based interview and examination or patient self-assessment, and consist of rating scales and questionnaires. These evaluations provide estimations of conceptual, nonobservable factors (e.g., symptoms), usually scored on an ordinal scale. The second type of measure is objective, factual, based on technology-based devices capturing physical characteristics of the pathological phenomena (e.g., sensors to measure the frequency and amplitude of tremor). These instrumental evaluations furnish appraisals with real numbers on an interval scale for which a unit exists. In both categories of measures, a broad variety of tools exist. This chapter aims to present an up-to-date summary of the most relevant characteristics of the most widely used scales, questionnaires, and technological resources currently applied to the assessment of PD. The review concludes that, in our opinion: (1) no assessment methods can substitute the clinical judgment and (2) subjective and objective measures in PD complement each other, each method having strengths and weaknesses.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ambulatory monitoring; Body-fixed sensors; Objective assessment; Questionnaires; Scales; Sensors; Wearables

Mesh:

Year:  2017        PMID: 28554406     DOI: 10.1016/bs.irn.2017.01.001

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  18 in total

Review 1.  Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review.

Authors:  Raquel Bouça-Machado; Gonçalo S Duarte; Maria Patriarca; Ana Castro Caldas; Joana Alarcão; Ricardo M Fernandes; Tiago A Mestre; Ricardo Matias; Joaquim J Ferreira
Journal:  Mov Disord Clin Pract       Date:  2019-12-11

2.  Will Artificial Intelligence Outperform the Clinical Neurologist in the Near Future? Yes.

Authors:  Roongroj Bhidayasiri
Journal:  Mov Disord Clin Pract       Date:  2021-04-12

3.  Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.

Authors:  Stylianos Ravanidis; Anastasia Bougea; Dimitra Karampatsi; Nikolaos Papagiannakis; Matina Maniati; Leonidas Stefanis; Epaminondas Doxakis
Journal:  Mov Disord       Date:  2021-01-12       Impact factor: 10.338

Review 4.  Internet of Things Technologies and Machine Learning Methods for Parkinson's Disease Diagnosis, Monitoring and Management: A Systematic Review.

Authors:  Konstantina-Maria Giannakopoulou; Ioanna Roussaki; Konstantinos Demestichas
Journal:  Sensors (Basel)       Date:  2022-02-24       Impact factor: 3.576

5.  Analysis of Correlation between an Accelerometer-Based Algorithm for Detecting Parkinsonian Gait and UPDRS Subscales.

Authors:  Alejandro Rodríguez-Molinero; Albert Samà; Carlos Pérez-López; Daniel Rodríguez-Martín; Leo R Quinlan; Sheila Alcaine; Berta Mestre; Paola Quispe; Benedetta Giuliani; Gabriel Vainstein; Patrick Browne; Dean Sweeney; J Manuel Moreno Arostegui; Àngels Bayes; Hadas Lewy; Alberto Costa; Roberta Annicchiarico; Timothy Counihan; Gearòid Ò Laighin; Joan Cabestany
Journal:  Front Neurol       Date:  2017-09-01       Impact factor: 4.003

Review 6.  Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review.

Authors:  Carmen Rodríguez-Blázquez; Maria João Forjaz; Monica M Kurtis; Roberta Balestrino; Pablo Martinez-Martin
Journal:  Front Neurol       Date:  2018-06-07       Impact factor: 4.003

7.  Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation.

Authors:  Zhan-Miao Yi; Ting-Ting Qiu; Yuan Zhang; Na Liu; Suo-Di Zhai
Journal:  Ther Clin Risk Manag       Date:  2018-04-16       Impact factor: 2.423

8.  Exploring Bedroom Usability and Accessibility in Parkinson's Disease (PD): The Utility of a PD Home Safety Questionnaire and Implications for Adaptations.

Authors:  Roongroj Bhidayasiri; Onanong Jitkritsadakul; Jirada Sringean; Thitiporn Jantanapornchai; Nitinan Kantachadvanich; Saisamorn Phumphid; Kamolwan Boonpang; Sarawan Pensook; Nicharee Aungkab; Nobutaka Hattori; K Ray Chaudhuri
Journal:  Front Neurol       Date:  2018-05-17       Impact factor: 4.003

Review 9.  Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed.

Authors:  Nataliya Titova; Pablo Martinez-Martin; Elena Katunina; K Ray Chaudhuri
Journal:  J Neural Transm (Vienna)       Date:  2017-11-07       Impact factor: 3.575

10.  Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients.

Authors:  Stylianos Ravanidis; Anastasia Bougea; Nikolaos Papagiannakis; Christos Koros; Athina Maria Simitsi; Ioanna Pachi; Marianthi Breza; Leonidas Stefanis; Epaminondas Doxakis
Journal:  Ann Clin Transl Neurol       Date:  2020-08-29       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.